The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data

Journal of Affective Disorders, Journal Year: 2023, Volume and Issue: 348, P. 314 - 322

Published: Dec. 23, 2023

Language: Английский

---

Depression-like phenotypes in mice following common bile duct ligation: Insights into the gut–liver–brain axis via the vagus nerve

Neurobiology of Disease, Journal Year: 2024, Volume and Issue: 192, P. 106433 - 106433

Published: Feb. 7, 2024

Depression frequently occurs in patients with liver cirrhosis, yet the reasons for this correlation are not fully understood. Dysbiosis of gut microbiota has been implicated depression through gut–brain axis via vagus nerve. This study explored potential role gut–liver–brain nerve depression-like phenotypes mice cirrhosis. These underwent common bile duct ligation (CBDL), a method used to stimulate To assess behaviors, behavioral tests were conducted 10 days following either sham or CBDL surgeries. The displayed symptoms such as splenomegaly, elevated plasma levels interleukin-6 and tumor necrosis factor-α, decreased synaptic proteins prefrontal cortex (PFC), disrupted balance, changes blood metabolites (or lipids). Additionally, there positive negative correlations between relative abundance microbiome data Significantly, these reversed by performing subdiaphragmatic vagotomy. Intriguingly, improved after single injection arketamine, new antidepressant. results suggest that CBDL-induced mediated nerve, arketamine might offer treatment approach cirrhosis patients.

Language: Английский

---

Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions

Journal of Anesthesia and Translational Medicine, Journal Year: 2024, Volume and Issue: 3(3), P. 65 - 75

Published: July 11, 2024

Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, similarly employed for anesthesia analgesia. The anesthetic effects of ketamine esketamine arise from their antagonism the N-methyl-D-aspartate receptor (NMDAR). In field psychiatry, rapid-acting antidepressant properties severe depression have generated significant interest, resulting its increased off-label usage United States (U.S.). 2019, nasal spray received approval use U.S. Europe. However, concerns emerged regarding potential adverse effects, including long-term efficacy, addiction risks, suicide risk clinical settings. contrast, arketamine, (R)-enantiomer ketamine, exhibits superior longer-lasting rodent models depression, with fewer side compared to esketamine. Nevertheless, research on efficacy safety arketamine patients remains limited. This article provides concise exploration historical two enantiomers while also delving into future directions application these fields.

Language: Английский

---

(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6804 - 6804

Published: June 20, 2024

NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative epilepsy, traumatic brain injury, substance abuse disorder (SUD), major depressive (MDD). (S)-ketamine was the first of a novel class antidepressants, rapid-acting to be approved medical use. The stereoisomer, (R)-ketamine (arketamine), is currently under development treatment-resistant depression (TRD). compound has demonstrated efficacy multiple animal models. Two clinical studies disclosed TRD bipolar depression. A study by drug sponsor recently failed reach priori endpoints but post hoc analysis revealed efficacy. value supported experimental data humans rodents, showing that it less sedating, does not produce marked psychotomimetic or dissociative effects, than (S)-ketamine, produces models range disorders. mechanisms action antidepressant effects are hypothesized due antagonism and/or non-NMDA mechanisms. We suggest further experimentation with will create improved medicines some disorders underserved current medications.

Language: Английский

---

The vagus nerve: An old but new player in brain–body communication

Brain Behavior and Immunity, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 1, 2024

Language: Английский

---

A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model

Neuropharmacology, Journal Year: 2022, Volume and Issue: 219, P. 109250 - 109250

Published: Sept. 9, 2022

Language: Английский

---

Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice

Pharmacology Biochemistry and Behavior, Journal Year: 2022, Volume and Issue: 222, P. 173500 - 173500

Published: Dec. 5, 2022

Language: Английский

---

A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice

Translational Psychiatry, Journal Year: 2022, Volume and Issue: 12(1)

Published: Sept. 28, 2022

(R,S)-ketamine is known to elicit persistent prophylactic effects in rodent models of depression. However, the precise molecular mechanisms underlying its action remain elusive. Using RNA-sequencing analysis, we searched for novel target(s) that contribute (R)-ketamine, a more potent enantiomer chronic restraint stress (CRS) model. Pretreatment with (R)-ketamine (10 mg/kg, 1 day before CRS) significantly ameliorated body weight loss, increased immobility time forced swimming test, and decreased sucrose preference test CRS-exposed mice. analysis prefrontal cortex (PFC) revealed several miRNAs such as miR-132-5p might sustained (R)-ketamine. Methyl CpG binding protein 2 (MeCP2) regulate brain-derived neurotrophic factor (BDNF) expression. Quantitative RT-PCR confirmed attenuated altered expression regulated genes (Bdnf, Mecp2, Tgfb1, Tgfbr2) PFC Furthermore, BDNF, MeCP2, TGF-β1 (transforming growth β1), synaptic proteins (PSD-95, GluA1) Administration agomiR-132-5p Bdnf Tgfb1 PFC, resulting depression-like behaviors. In contrast, administration antagomiR-132-5p blocked mice, antidepressant-like effects. conclusion, our data show role phenotypes CRS model

Language: Английский

---

Esmethadone-HCl (REL-1017): a promising rapid antidepressant

European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2023, Volume and Issue: 273(7), P. 1463 - 1476

Published: March 8, 2023

Abstract This review article presents select recent studies that form the basis for development of esmethadone into a potential new drug. Esmethadone is promising member pharmacological class uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists have shown efficacy major depressive disorder (MDD) and other diseases disorders, such as Alzheimer’s dementia pseudobulbar affect. The drugs in novel NMDAR with therapeutic uses are discussed comparative purposes this esketamine, ketamine, dextromethorphan, memantine. We present silico, vitro, vivo, clinical data may advance our understanding role these receptors neural plasticity health disease. rapid antidepressants neurobiology MDD neuropsychiatric disorders.

Language: Английский

---

Efficacy and safety of esketamine for perioperative depression in patients undergoing elective surgery: A meta-analysis of randomized controlled trials

Asian Journal of Psychiatry, Journal Year: 2024, Volume and Issue: 95, P. 103997 - 103997

Published: March 11, 2024

Language: Английский

---